MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL)

Historical Holders from Q2 2016 to Q3 2025

Symbol
MDGL on Nasdaq
Type / Class
Equity / Common Stock, Par Value $0.0001 Per Share
Shares outstanding
23.3M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
23.4M
Holdings value
$10.7B
% of all portfolios
0.016%
Grand Portfolio weight change
0%
Number of holders
346
Number of buys
187
Number of sells
-145
Average Value change %
0%
Average buys %
+0.004%
Average sells %
-0.007%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 8.3% -16% $845M -$160M 1.84M -15.9% JANUS HENDERSON GROUP PLC 30 Sep 2025
FRIEDMAN PAUL A 7.8% $983M 1.81M Paul A Friedman, M.D. 10 Dec 2025
Taub Rebecca 7.8% $983M 1.81M Rebecca Taub, M.D. 10 Dec 2025

Institutional Holders of MADRIGAL PHARMACEUTICALS, INC. - Common Stock, Par Value $0.0001 Per Share (MDGL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 23.4M $10.7B -$22M $458.66 346
2025 Q2 23.6M $7.13B -$59M $302.64 303
2025 Q1 23.6M $7.82B +$242M $331.23 317
2024 Q4 23M $7.08B +$127M $308.57 282
2024 Q3 22.6M $4.76B -$107M $212.22 252
2024 Q2 22.9M $6.41B +$505M $280.16 255
2024 Q1 21.1M $5.63B +$377M $267.04 263
2023 Q4 19.8M $4.57B +$603M $231.38 225
2023 Q3 17.4M $2.54B +$349M $146.04 206
2023 Q2 14.8M $3.43B +$220M $231.00 208
2023 Q1 13.9M $3.36B +$107M $242.26 221
2022 Q4 13.3M $3.86B +$567M $290.25 186
2022 Q3 11.8M $764M -$25.3M $64.99 133
2022 Q2 12M $858M -$17.3M $71.58 130
2022 Q1 12M $1.18B +$26.3M $98.12 132
2021 Q4 12M $1.01B +$40.9M $84.74 139
2021 Q3 11M $875M -$34.3M $79.79 126
2021 Q2 11.2M $1.09B -$99.1M $97.41 147
2021 Q1 12.2M $1.43B -$10.2M $116.97 135
2020 Q4 12.3M $1.36B +$68.9M $111.17 132
2020 Q3 11.6M $1.38B +$46.5M $118.73 125
2020 Q2 11.3M $1.27B +$4.79M $113.25 124
2020 Q1 11M $738M +$26.6M $66.76 106
2019 Q4 10.5M $954M +$65.9M $91.11 119
2019 Q3 9.64M $831M -$23.3K $86.22 108
2019 Q2 9.61M $1.01B +$10.3M $104.81 115
2019 Q1 9.46M $1.18B +$61.3M $125.26 133
2018 Q4 8.98M $1.01B -$4.92M $112.72 130
2018 Q3 8.62M $1.85B +$62.7M $214.13 153
2018 Q2 8.12M $2.27B +$574M $279.69 148
2018 Q1 6.33M $739M +$152M $116.79 98
2017 Q4 5.13M $471M +$234M $91.79 88
2017 Q3 2.67M $120M +$29M $44.98 50
2017 Q2 2.05M $33.3M +$8.86M $16.26 39
2017 Q1 1.53M $23.5M +$3.02M $15.40 25
2016 Q4 1.35M $20M +$6.3M $14.90 24
2016 Q3 1.01M $12.8M +$12.7M $12.67 24
2016 Q2 79.6K $21K +$21K $0.26 1